Antianxiety effects of dexmedetomidine: systematic review and meta-analysis
- PMID: 40372453
- DOI: 10.1007/s00406-025-02017-9
Antianxiety effects of dexmedetomidine: systematic review and meta-analysis
Abstract
Background: Despite numerous studies of the anxiolytic effects of dexmedetomidine compared with those of other drugs or saline, the results have been inconsistent. Here we report a systematic review and meta-analysis to comprehensively evaluate the evidence of the anxiolytic effects of dexmedetomidine.
Methods: This research has been registered in the International Prospective Register of Systematic Reviews. The PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov database were searched for clinical trials that compared the anxiolytic effects of dexmedetomidine with those of a control group with valid anxiety scores from inception to December 29, 2024.
Results: Overall, this systematic review and meta-analysis included 25 clinical studies with 2159 participants who underwent surgery. The primary outcome revealed that patients who were treated with dexmedetomidine had significantly lower anxiety scores than others did overall (MD = - 1.73, 95% CI = [ - 2.33, - 1.13], p < 0.00001, I2 = 86.5%). Dexmedetomidine was found to be more effective than benzodiazepines in relieving anxiety (MD = - 1.34, 95% CI = [ - 2.08, - 0.60], p = 0.0004, I2 = 83.3%). The secondary outcomes revealed no significant differences in satisfaction, pain level, sedation scores or the risk of postoperative nausea and vomiting between patients who were treated with dexmedetomidine and controls. However, the occurrence of bradycardia was more common in the dexmedetomidine groups.
Conclusions: Overall, this meta-analysis provided evidence of the potential of dexmedetomidine for relieving anxiety among patients who undergo surgery, with superior antianxiety effects compared with those of benzodiazepines.
Keywords: Anxiety; Benzodiazepines; Dexmedetomidine; Meta-analysis.
© 2025. Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: All the authors declare no competing interests. Ethical approval: Not applicable. Consent for publication: Not applicable.
Similar articles
-
The Effect of Dexmedetomidine on Postanesthesia Care Unit Discharge and Recovery: A Systematic Review and Meta-Analysis.Anesth Analg. 2022 Jun 1;134(6):1229-1244. doi: 10.1213/ANE.0000000000005843. Epub 2022 Jan 27. Anesth Analg. 2022. PMID: 35085107
-
An evaluation of dexmedetomidine in combination with midazolam in pediatric sedation: a systematic review and meta-analysis.BMC Anesthesiol. 2024 Jun 21;24(1):210. doi: 10.1186/s12871-024-02570-1. BMC Anesthesiol. 2024. PMID: 38907338 Free PMC article.
-
Dexmedetomidine as an adjunct to local anesthetics in nerve block relieved pain more effectively after TKA: a meta-analysis of randomized controlled trials.J Orthop Surg Res. 2020 Dec 1;15(1):577. doi: 10.1186/s13018-020-02105-7. J Orthop Surg Res. 2020. PMID: 33261646 Free PMC article.
-
Effects of Dexmedetomidine on Emergence Agitation and Recovery Quality Among Children Undergoing Surgery Under General Anesthesia: A Meta-Analysis of Randomized Controlled Trials.Front Pediatr. 2020 Nov 13;8:580226. doi: 10.3389/fped.2020.580226. eCollection 2020. Front Pediatr. 2020. PMID: 33304867 Free PMC article.
-
Dexmedetomidine versus remifentanil for controlled hypotension under general anesthesia: A systematic review and meta-analysis.PLoS One. 2023 Jan 17;18(1):e0278846. doi: 10.1371/journal.pone.0278846. eCollection 2023. PLoS One. 2023. PMID: 36649357 Free PMC article.
References
-
- Penninx BW, Pine DS, Holmes EA et al (2021) Anxiety disorders. Lancet 397(10277):914–927. https://doi.org/10.1016/S0140-6736(21)00359-7 - DOI - PubMed - PMC
-
- GBD 2019 Diseases and Injuries Collaborators (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396(10258):1204–1222. https://doi.org/10.1016/S0140-6736(20)30925-9 - DOI
-
- COVID-19 Mental Disorders Collaborators (2021) Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 398(10312):1700–1712. https://doi.org/10.1016/S0140-6736(21)02143-7 - DOI
-
- Lamers F, van Oppen P, Comijs HC et al (2011) Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry 72(3):341–348. https://doi.org/10.4088/JCP.10m06176blu - DOI - PubMed
-
- Alonso J, Liu Z, Evans-Lacko S et al (2018) Treatment gap for anxiety disorders is global: results of the World Mental Health Surveys in 21 countries. Depress Anxiety 35(3):195–208. https://doi.org/10.1002/da.22711 - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources